Thromboxane synthetase inhibition in primary pulmonary hypertension.
Thromboxane synthetase inhibition in primary pulmonary hypertension.
复制标题
原发性肺动脉高压中的血栓素合成酶抑制。
作者:
S. Rich;Kimberley Hart;Karen Kieras;Bruce H. Brundage
Thromboxane synthetase inhibitors have been shown to reduce thromboxane, a potent vasoconstrictor, and increase prostacyclin, a potent vasodilator, in normal subjects. We evaluated the acute and chronic (three months) effects of the thromboxane synthetase inhibitor CGS13080 administered 200 mg every six hours on the resting hemodynamics in ten patients with primary pulmonary hypertension (PPH), and on their response to 20 mg of nifedipine given sublingually before and after the thromboxane synthetase inhibitor treatment. It was concluded that one can modulate the levels of endogenous thromboxane and prostacyclin in patients with primary pulmonary hypertension using a thromboxane synthetase inhibitor. Although the thromboxane synthetase inhibitor alone produced only modest hemodynamic changes over time, the addition of nifedipine was able to produce a further lowering of pulmonary artery pressure and pulmonary vascular resistance.
登录
查看更多内容
影响因子:
9.6
作者:
Barst,RJ;Stalcup,SA
通讯作者:
Stalcup,SA
DOI:
10.1164/arrd.1985.131.1.171
发表时间:
1985
期刊:
The American review of respiratory disease
影响因子:
--
作者:
Barst,RJ;Stalcup,SA;Steeg,CN;Hall,JC;Frosolono,MF;Cato,AE;Mellins,RB
通讯作者:
Mellins,RB
DOI:
--
发表时间:
1982
期刊:
Advances in prostaglandin, thromboxane, and leukotriene research
影响因子:
--
作者:
Kadowitz,PJ;Lippton,HL;McNamara,DB;Spannhake,EW;Hyman,AL
通讯作者:
Hyman,AL
DOI:
10.1056/nejm198104233041703
发表时间:
1981
期刊:
The New England journal of medicine
影响因子:
--
作者:
Robertson,RM;Robertson,D;Roberts,LJ;Maas,RL;FitzGerald,GA;Friesinger,GC;Oates,JA
通讯作者:
Oates,JA
影响因子:
39.2
作者:
Rubin,LJ;Nicod,P;Hillis,LD;Firth,BG
通讯作者:
Firth,BG